Evidence map›Paper›PMID 27304216›Full record

ArticlePloS one2016

Fibulin-5 Regulates Angiopoietin-1/Tie-2 Receptor Signaling in Endothelial Cells.

Wilson Chan, Hodan Ismail, Dominique Mayaki, Veronica Sanchez, Kerstin Tiedemann, Elaine C Davis, Sabah N A Hussain

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Engeletin protects against cerebral ischemia/reperfusion injury by modulating the VEGF/vasohibin and Ang-1/Tie-2 pathways.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2021
    Article
  13. Article
  14. Article
  15. A Single-Cell Transcriptome Atlas of the Mouse Glomerulus.Journal of the American Society of Nephrology : JASN · 2018
    Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Wilson ChanDepartment of Anatomy and Cell Biology, McGill University, Montréal, QC, Canada.
Hodan IsmailTranslational Research in Respiratory Diseases, McGill University Health Centre, and Meakins-Christie Laboratories, Department of Medicine, McGill University, Montréal, QC, Canada.
Dominique MayakiTranslational Research in Respiratory Diseases, McGill University Health Centre, and Meakins-Christie Laboratories, Department of Medicine, McGill University, Montréal, QC, Canada.
Veronica SanchezTranslational Research in Respiratory Diseases, McGill University Health Centre, and Meakins-Christie Laboratories, Department of Medicine, McGill University, Montréal, QC, Canada.
Kerstin TiedemannFaculty of Dentistry, McGill University and Shriners Hospital for Children, Montréal, QC, Canada.
Elaine C DavisDepartment of Anatomy and Cell Biology, McGill University, Montréal, QC, Canada.
Sabah N A HussainTranslational Research in Respiratory Diseases, McGill University Health Centre, and Meakins-Christie Laboratories, Department of Medicine, McGill University, Montréal, QC, Canada.
McGill University Health Centre · CAMcGill University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFibulin-5 is an extracellular matrix glycoprotein that plays critical roles in vasculogenesis and embryonic development. Deletion of Fibulin-5 in mice results in enhanced skin vascularization and upregulation of the angiogenesis factor angiopoietin-1 (Ang-1), suggesting that Fibulin-5 functions as an angiogenesis inhibitor. In this study, we investigate the inhibitory effects of Fibulin-5 on Ang-1/TIE-2 receptor pathway signaling and cell survival in human endothelial cells. METHODOLOGY/PRINCIPAL

findingsRecombinant wild-type and RGE-mutant Fibulin-5 proteins were generated through stable transfection of HEK293 and CHO cells, respectively. In vitro solid phase binding assays using pure proteins revealed that wild-type Fibulin-5 does not bind to Ang-1 or TIE-2 proteins but strongly binds to heparin. Binding assays using human umbilical vein endothelial cells (HUVECs) indicated that wild-type Fibulin-5 strongly binds to cells but RGE-mutant Fibulin-5, which is incapable of binding to integrins, does not. Pre-incubation of HUVECs for 1 hr with Fibulin-5 significantly increased caspase 3/7 activity, ERK1/2 phosphorylation, and expressions of the transcription factor early growth response 1 (EGR1) and the dual-specificity phosphatase 5 (DUSP5). Fibulin-5 also strongly attenuated Ang-1-induced TIE-2 and AKT phosphorylation, decreased Ang-1-induced expressions of the transcription factors Inhibitor of DNA Binding 1 (ID1) and Kruppel-like Factor 2 (KLF2), and reversed the inhibitory effect of Ang-1 on serum deprivation-induced cytotoxicity and caspase 3/7 activity. CONCLUSION/SIGNIFICANCE: We conclude that Fibulin-5 strongly binds to the endothelial cell surface through heparin-sulfate proteoglycans and possibly integrins and that it exerts strong anti-angiogenic effects by reducing endothelial cell viability and interfering with the signaling pathways of the Ang-1/TIE-2 receptor axis.

Indexed as

Signal TransductionAngiopoietin-1AnimalsCells, CulturedCell SurvivalCHO CellsCricetinaeCricetulusEarly Growth Response Protein 1Extracellular Matrix ProteinsGene ExpressionHEK293 CellsHumansHuman Umbilical Vein Endothelial CellsImmunoblottingInhibitor of Differentiation Protein 1Angiopoietin-1Early Growth Response Protein 1EGR1 protein, humanExtracellular Matrix ProteinsFBLN5 protein, humanID1 protein, humanInhibitor of Differentiation Protein 1KLF2 protein, humanKruppel-Like Transcription FactorsReceptor, TIE-2Recombinant Proteins

Identifiers

PMID27304216
PMCPMC4909301
OpenAlexW2431514577

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.